Barbados’ private pharmacy community has launched a thorough review of the newly approved Medical Products Act this week, with stakeholders flagging potential risks to the country’s domestic pharmaceutical supply chain and long-standing regulatory framework. The comprehensive legislation, which cleared the Senate before securing final passage in the House of Assembly on Tuesday, was crafted to ramp up oversight of drug quality and distribution, crack down on counterfeit medications, and cut Barbados’ overreliance on foreign pharmaceutical suppliers.
Marlon Ward Rogers, president of the Pharmaceutical Society of Barbados, confirmed to local outlet Barbados TODAY on Wednesday that his organization is conducting a line-by-line examination of the bill’s provisions to assess its full impact on the island’s pharmaceutical industry. “We are still discussing and analyzing every section to understand what changes are ahead. We are in the process of a full review, and we will need to hold a full meeting to map out implications. The legislation just completed its parliamentary process this week, so we are still waiting to see if any further adjustments are made and what the government’s next implementation steps will be,” Ward Rogers stated, declining to share further comment ahead of the organization’s full review.
The bill marks a historic milestone for Barbados’ legislative process: Health Minister Lisa Cummins, a Senator, introduced the legislation to the House of Assembly under new constitutional rules adopted late last year that allow cross-chamber appearances. Speaking during the debate, Cummins emphasized that the new law is designed to build full medical products sovereignty for Barbados, with public safety at its core. The legislation’s central priority is shielding Barbadians from the life-threatening risks posed by counterfeit and substandard pharmaceuticals.
Cummins highlighted Section 6 of the act, which overhauls the process for medical product registration and marketing authorization, as a critical cornerstone of the new regulatory regime. The updated rules are necessary, she explained, to protect the public from fraudulent medications and products marketed with false claims about their therapeutic effectiveness. “This legislation’s core mission is to protect the Barbadian community through strong regulation: it targets counterfeit drugs, and products that are advertised to deliver specific health benefits but do not live up to those claims,” the minister added.
Another key provision of the law paves the way for the establishment of Barbados Pharmaceutical Inc., a state-owned domestic pharmaceutical production company. According to Cummins, the new entity will position Barbados to expand its role in the regional pharmaceutical ecosystem, evolving from its current status as a regional logistics hub into a full-spectrum center for pharmaceutical manufacturing, distribution, and regulatory oversight for the entire Caribbean region.